Previous 10 | Next 10 |
GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug...
Recro Pharma (REPH) shares rise nearly 7% during premarket trading after announcing the signing of a new development agreement with Astex Pharmaceuticals.Recro is a contract development and manufacturing organization ((CDMO)), providing oral solid dosage form development, end-to-end...
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products...
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formula...
Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianlu...
Recro Pharma (REPH) has priced its public offering of ~13.3M shares of common stock at $2.25/share, for expected gross proceeds of ~$30M.Underwriters' over-allotment is an additional ~2M shares. Net proceeds will be used for general corporate purposes, including repayment of outstanding debt ...
EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, toda...
Recro Pharma (REPH) trades 3.9% down after hours on planning to offer and sell shares in an underwritten public offering; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms not yet disclosed.Net proceeds to be used for general...
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, toda...
The following slide deck was published by Recro Pharma, Inc. in conjunction with this event. For further details see: Recro Pharma Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...